<DOC>
	<DOCNO>NCT00943592</DOCNO>
	<brief_summary>This clinical research study design evaluate whether condition regimen consist combination three drug name melphalan , alemtuzumab clofarabine support donor blood cell result rapid recovery high rate long-lasting remission patient leukemia , lymphoma myeloma .</brief_summary>
	<brief_title>Clofarabine-Melphalan-Alemtuzumab Conditioning Patients With Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Relapsed refractory acute myelogenous lymphoid leukemia Chronic myelogenous leukemia accelerate phase blastcrisis Chronic myelogenous leukemia second subsequent chronic phase Recurrent refractory malignant lymphoma Hodgkin 's disease Multiple myeloma high risk disease recurrence Chronic lymphocytic leukemia , relapse poor prognostic feature Other Myeloproliferative disorder ( polycythemia vera , essential thrombocythemia , myelofibrosis ) poor prognostic feature Myelodysplastic syndrome ( include PNH ) &gt; 5 % blast Zubroid performance status &lt; 2 ( See Appendix B ) Life expectancy severely limited concomitant illness Adequate cardiac pulmonary function . Patients decrease LVEF PFTS evaluate cardiology pulmonary prior enrollment protocol Calculated Creatinine Clearance &gt; 50 ml/min Serum bilirubin 2.0 mg/dl , SGPT &lt; 3x upper limit normal No evidence chronic active hepatitis cirrhosis HIVnegative Patient pregnant Patient guardian able sign inform consent Clinical progression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Melphalan</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Clofarabine</keyword>
</DOC>